Soleno Therapeutics Posts $94.6M Revenue, $0.59 EPS in Strong Q1 2026 Driven by VYKAT XR Launch
summarizeSummary
Soleno Therapeutics reported robust first-quarter 2026 results, posting $94.6 million in revenue and diluted earnings per share of $0.59. This marks a significant turnaround from no product revenue and a loss in the prior-year quarter, driven by the successful commercial launch of VYKAT XR following its FDA approval in March 2025. While recent timeline events focused on a tender offer, this 10-Q provides crucial operational performance data, demonstrating the company's successful transition to commercialization and profitability. The strong financial performance validates the product strategy and provides a solid financial runway. Investors will now monitor the continued growth trajectory of VYKAT XR sales and the company's ability to sustain profitability.
At the time of this announcement, SLNO was trading at $52.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $29.43 to $90.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.